Harvard’s Onconephrology Symposium 2026 focuses on kidney problems that arise from cancer and its treatment. The September 17–18 program connects nephrology with hematology, oncology, transplantation, pathology, and supportive care. Sessions explore immune checkpoint inhibitor injury, stem cell and cellular therapies, kidney function assessment, chemotherapy dosing, proteinuria, and renal-protective strategies. The second day turns to amyloidosis, monoclonal gammopathies, light chain injury, and transplant-related challenges, with case reviews and debates. Directed by Shruti Gupta and Raad Chowdhury, the course is designed for clinicians managing these overlapping conditions. The supplied two-day Topics list and original objectives are presented below without repeated session summaries.
Learning Objectives
After completing the original educational activity, participants should be better able to:
- Diagnose and manage different forms of kidney complications occurring in patients with cancer, including acute kidney injury, chronic kidney disease, glomerular disorders, and treatment-associated nephrotoxicity.
- Apply multidisciplinary approaches involving nephrologists, oncologists, hematologists, transplant specialists, pathologists, cardiologists, and palliative care clinicians to improve the care of patients with malignancy.
- Recognize cancer-associated glomerular disease, thrombotic microangiopathy, and monoclonal gammopathies while reviewing advances in diagnostic testing and management.
- Evaluate the role of kidney transplantation in patients with active or previous malignancy and understand important transplant-related oncologic complications.
- Review conventional chemotherapy, cellular therapy, immunotherapy, and targeted cancer therapies, including their potential renal complications.
- Explore current and emerging strategies to reduce kidney injury during cancer treatment.
- Assess immune checkpoint inhibitor-associated kidney complications and emerging diagnostic biomarkers.
- Review renal implications of hematopoietic stem cell transplantation and cellular immunotherapy.
- Recognize the clinical importance of proteinuria, hypertension, altered glomerular filtration rate, and drug-associated renal toxicity in patients receiving cancer treatment.
- Integrate current knowledge of monoclonal gammopathies, amyloidosis, multiple myeloma, and light chain-mediated kidney injury into clinical decision-making.
Topics
Day 1: Thursday, September 17, 2026
- Registration / Breakfast
- Welcome From Course Directors
- Welcome Message from a Pioneer
- What Do BMT Docs Wish Nephrologists Knew about HSCT? (Includes Q&A)
- Changing Diagnostic and Treatment Landscape of HSCT-TMA (Includes Q&A)
- Cancer and Complementology (Includes Q&A)
- Murine Models and Immune Therapy: What Can Mice Teach us About AIN? (Includes Q&A)
- Break
- Beyond Biopsy: Biomarkers and Treatments for ICI-AKI (Includes Q&A)
- Lessons from Non-Renal Immune Related Adverse Events (Includes Q&A)
- ICI-GN: A Conundrum (Includes Q&A)
- Lunch Break / Poster Review
- Toxicities of CAR-T and CAR-Treg
- How Tumor Infiltrating Lymphocytes are Transforming Cancer Treatment
- Q&A (Toxicities of CAR-T/CAR-Treg & Tumor Infiltrating Lymphocytes)
- MAGnificent properties of Cisplatin: mitigating risk and managing AKI (Includes Q&A)
- Target Trial Emulation in Onconephrology (Includes Q&A)
- What’s the GFR!? Current Challenges in Cancer and Future Opportunities (Includes Q&A)
- How Would I Dose Chemotherapy? A Case Review (Includes Q&A)
- Break
- Podocytes: An Innocent Bystander in Cancer (Includes Q&A)
- Novel Treatments for Proteinuria and Hypertension: Is there a Role for Endothelin Inhibitors? (Includes Q&A)
- SGLT2is: Are they a Miracle For Cancer- Associated Nephrotoxicity Too? (Includes Q&A)
- Immune Complex Disease in Cancer: Future of Antigens (Includes Q&A)
- Nephrocentric vs Nephrotolerant: When is it Safe to Rechallenge? (Includes Q&A)
- Palliative Care in Onconephrology: Symptom Management and Decision Support (Includes Q&A)
- Adjourn
Day 2: Friday, September 18, 2026
- Registration / Breakfast
- The Other Renal Amyloids: It’s not ALL about AL Amyloid (Includes Q&A)
- Pathophysiology of Cancer Therapy and Cardiotoxicity (Includes Q&A)
- MGUS to Myeloma: Bench to the Bedside (Includes Q&A)
- IKMG Update on MGRS: Future Associations and Mechanisms (Includes Q&A)
- How do Immunoglobulins Cause Kidney Damage?
- Q&A (IKMG Update on MGRS & Immunoglobulins Causing Kidney Damage)
- Break
- The Onconephrology Jeopardy Challenge (Includes Q&A)
- How I Manage IgM Disease and Systemic Impact (Includes Q&A)
- Light Chain Cast Nephropathy: Beyond Plex (CAR-T, Bispecific) (Includes Q&A)
- The Clone That Stole the Gift: Transplant MGRS Case Review (Includes Q&A)
- Post Kidney Transplant Lymphoproliferative Disorders: Perspectives from a Transplant Nephrologist (Includes Q&A)
- The War Against Light Chains: A Case Debate (Includes Q&A)
- Final Reflections / Poster Winners
- Break
Faculty
- Shruti Gupta, MD, MPH
- Raad Chowdhury, MD, FASN
- Joseph Bonventre
- Corey Cutler, MD, MPH
- Sumithra Vasu, MD
- Anuja Java, MD
- Sandra Herrmann, MD
- Meghan Sise, MD
- Elad Sharon, MD, MPH
- Abdullah Jalal, MD
- Ala Abudayyeh, MD
- Sarah Nikiforow, MD, PhD
- Allison Betof, MD, PhD
- Edgar Jaimes
- David E. Leaf, MD
- Aisha Shaikh, MD, PhD
- Abhijat Kitchlu, MD, MSc, FRCPC
- Astrid Weins, MD, PhD
- Api Chewcharat, MD
- María José Soler, MD, PhD
- Sujal Shah, MD
- Biruh Workeneh, MD, FASN
- Harish Seethapathy, MD
- Samantha Gelfand, MD
- Vaishali Sanchorawala, MD
- Anju Nohria
- Nikhil C. Munshi, MD
- Samih H. Nasr, MD
- Christophe Sirac, PhD
- Kenar Jhaveri, MD
- Jorge J. Castillo, MD
- Nelson Leung, MD
- Christopher Blosser, MD
Program scope: The supplied Topics list describes the original program. Breaks, workshops, discussions, and other agenda entries do not establish that every scheduled activity is included in the recordings.
File scope: This purchase covers the educational files offered by MedicalAmboss. Event attendance, publisher-platform access, accounts, memberships, apps, and publisher-hosted extras are not included.



